Title:Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?
VOLUME: 20 ISSUE: 13
Author(s):Hang Hock Shim*, Christopher Ma, Paulo Gustavo Kotze and Remo Panaccione
Affiliation:Department of Gastroenterology and Hepatology, Singapore General Hospital, Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary
Keywords:Ustekinumab, Crohn's disease, surgery, chronic inflammatory, biologic therapies, vedolizumab.
Abstract:Crohn’s disease (CD) is a chronic inflammatory condition of the intestinal tract that is characterised
by a relapsing and remitting course. Despite advancements in therapeutic options for CD, a
substantial number of patients still require surgery for medically refractory disease or disease-related
complications. Given the widespread adoption of biologic therapies for the management of patients
with moderate-to-severe CD, a high number of patients are likely to be on biologic therapy at the time
of needing intestinal surgery: the safety of biologics in perioperative setting is of great interest. While
more clinical data are available for TNF antagonists and vedolizumab, the safety data for ustekinumab,
an IL 12/23 inhibitor, is lacking. Here, we review the available data from published literature on
the postoperative outcomes for CD patients exposed to ustekinumab perioperatively.
